News|Articles|September 9, 2013

Horizon Pharma Receives FDA Aprroval for Sanofi Site to Manufacturing Its Product

Author(s)Pharmaceutical Technology Editors

Horizon Pharma reports that FDA has approved the use of Sanofi's manufacturing site in Compiegne, France to manufacture DUEXIS.

Horizon Pharma, a specialty pharmaceutical company, announced that FDA has approved the use of Sanofi's manufacturing site in Compiegne, France to manufacture Duexis (ibuprofen/famotidine), a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg). Valeant Pharmaceuticals' manufacturing site in Laval, Quebec, previously owned and operated by Sanofi, serves as the primary commercial manufacturing site for Duexis.

Source: Horizon Pharma

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.